Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • Dominici M Le Blanc K Mueller I Slaper

    2022-09-15

    [36] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The Interna-tional Society for Cellular Therapy position statement. Cytotherapy 2006;8(4): 315–7.
    [37] Kuchimaru T, Kataoka N, Nakagawa K, Isozaki T, Miyabara H, Minegishi M, et al. A reliable murine model of bone metastasis by injecting cancer SPDP through caudal arteries. Nat Commun 2018;9. [38] Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast-Cancer. J Clin Oncol 1989;7(7):890–9. [39] Schneider T, Osl F, Friess T, Stockinger H, Scheuer WV. Quantification of human Alu sequences by real-time PCR–an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis 2002;19(7): 571–82.
    [42] Funakoshi K, Bagheri M, Zhou M, Suzuki R, Abe H, Akashi H. Highly sensitive and specific Alu-based quantification of human cells among rodent cells. Sci Rep-UK 2017;7.
    [43] Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7(9):678–89. [44] Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013;24(5):401–9.
    [45] Kucerova L, Durinikova E, Toro L, Cihova M, Miklikova S, Poturnajova M, et al. Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells. Cancer Lett 2017;408:1–9.
    [49] Stubke K, Wicklein D, Herich L, Schumacher U, Nehmann N. Selectin-deficiency re-duces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett 2012;321(1):89–99. [50] Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, et al. Murine models of breast cancer bone metastasis. Bonekey Rep 2016;5. [51] Andersen C, Bagi CM, Adams SW. Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats. J Musculoskelet Neuronal Interact 2003;3(2):148–55. [52] Karp JM, Teol GSL. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4(3):206–16. [53] Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by biolumines-cence imaging. Stem Cells 2009;27(7):1548–58. [54] Direcks WGE, van Gelder M, Lammertsma AA, Molthoff CFM. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo. Can-cer Biol Ther 2008;7(4):532–7.
    [55] Shaikh A, Bhartiya D, Kapoor S, Nimkar H. Delineating the effects of 5-fluorouracil and follicle-stimulating hormone on mouse bone marrow stem/progenitor cells. Stem Cell Res Ther 2016;7(1):59.
    [57] Michailidou M, Holen I. Combinations of bisphosphonates and classical anticancer drugs: a preclinical perspective. Recent Results Cancer Res 2012;192: 145–69.
    [66] Zhao WA, Loh W, Droujinine IA, Teo WS, Kumar N, Schafer S, et al. Mimicking the in-flammatory cell adhesion cascade by nucleic acid aptamer programmed cell-cell in-teractions. FASEB J 2011;25(9):3045–56. [67] Lorincz T, Timar J, Szendroi M. Alterations of microvascular density in bone metasta-ses of adenocarcinomas. Pathol Oncol Res 2004;10(3):149–53. [68] Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007;67(24):11687–95.
    [69] Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. Ex vivo gly-can engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14(2):181–7. [70] Bobis-Wozowicz S, Miekus K, Wybieralska E, Jarocha D, Zawisz A, Madeja Z, et al. Genetically modified adipose tissue-derived mesenchymal stem cells overexpress-ing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp Hematol 2011;39(6):686–696 e684.